Neumora Therapeutics, Inc. Common Stock (NMRA) Financial Ratios
6 years of historical data (2020–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
2.80
↓-42% vs avg
5yr avg: 4.82
30Y Low2.8·High5.9
ROE
↑
-121.2%
↓+84% vs avg
5yr avg: -769.6%
30Y Low-121%·High-64%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
NMRA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Neumora Therapeutics, Inc. Common Stock currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $330M | $292M | $1.7B | $2.7B | — | — | — |
| Enterprise Value | $148M | $110M | $1.5B | $2.3B | — | — | — |
| P/E Ratio → | -1.23 | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — |
| P/B Ratio | 2.80 | 2.82 | 5.89 | 5.77 | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
NMRA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
NMRA Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -121.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -121.2% | -121.2% | -64.5% | -2123.0% | — | — | — |
| ROA | -93.3% | -93.3% | -60.0% | -51.2% | -30.6% | -75.7% | -50.2% |
| ROIC | -527.4% | -527.4% | -160.0% | -140.8% | — | — | — |
| ROCE | -108.2% | -108.2% | -69.5% | -43.1% | -33.6% | -79.8% | -50.7% |
NMRA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $183M exceeds total debt of $477000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.01 | 0.01 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.75 | -0.49 | -0.79 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -72.56 | -72.56 | — | — | — | — | — |
Net cash position: cash ($183M) exceeds total debt ($477000)
NMRA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Neumora Therapeutics, Inc. Common Stock's current ratio of 5.87x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 19.05x to 5.87x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 5.87 | 5.87 | 10.51 | 19.05 | 16.37 | 17.85 | 20.69 |
| Quick Ratio | 5.87 | 5.87 | 10.51 | 19.05 | 16.37 | 17.85 | 20.69 |
| Cash Ratio | 5.62 | 5.62 | 10.29 | 18.08 | 15.69 | 17.58 | 20.49 |
| Asset Turnover | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — |
NMRA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Neumora Therapeutics, Inc. Common Stock does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $163M | $159M | $159M | $152M | $152M | $152M |
Peer Comparison
Compare NMRA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 NMRAYou | $330M | -1.2 | — | — | — | — | -121.2% | -527.4% | — |
 ACAD | $4B | 9.2 | 25.1 | 34.3 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 INVA | $2B | 6.9 | 6.8 | 8.6 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 AXSM | $13B | -69.3 | — | — | 92.6% | -26.5% | -252.1% | -1906.7% | — |
 PRAX | $8B | -19.8 | — | — | — | — | -45.8% | -65.0% | — |
 PTCT | $6B | 9.7 | 6.4 | 8.9 | 95.9% | 49.5% | — | — | 0.5 |
 NRXP | $66M | -2.9 | — | — | 58.8% | -1324.4% | — | — | — |
 ALTO | $441M | 35.6 | 15.6 | 50.9 | 3.8% | 0.8% | 5.7% | 1.9% | 3.0 |
 MNMD | $2B | -10.0 | — | — | — | — | -64.1% | -389.5% | — |
 LLY | $1.1T | 49.4 | 35.4 | 119.3 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
 PFE | $149B | 19.3 | 10.6 | 16.4 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
| Healthcare Median | — | 22.9 | 14.4 | 18.9 | 63.9% | -4.3% | -32.6% | -11.4% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 6 years · Updated daily
What if you invested $1,000 in NMRA 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in NMRA be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs NMRA Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationNMRA vs ACAD — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs ACADIA Pharmaceuticals Inc..
Compare NowNMRA — Frequently Asked Questions
Quick answers to the most common questions about buying NMRA stock.
What is Neumora Therapeutics, Inc. Common Stock's P/E ratio?
Neumora Therapeutics, Inc. Common Stock's current P/E ratio is -1.2x. This places it at the 50th percentile of its historical range.
What is Neumora Therapeutics, Inc. Common Stock's ROE?
Neumora Therapeutics, Inc. Common Stock's return on equity (ROE) is -121.2%. The historical average is -92.8%.
Is NMRA stock overvalued?
Based on historical data, Neumora Therapeutics, Inc. Common Stock is trading at a P/E of -1.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.